Riskpilot← Back to searchSign inGet full accessIK BioCeuticals AB
ABActiveOrg 5569366007Köpmangatan 38Activities of holding companies · NACE 6421Est. 20130 employees
Revenue 2024
SEK 64K
+408% vs 2023
EBITDA margin
-35.5%
-1357% vs 2023
Equity ratio
20.9%
Financial strength
Net profit 2024
SEK -22K
-2035% vs 2023
| Revenue | SEK 64K | +408% |
| EBITDA | SEK -23K | -1357% |
| Net profit | SEK -22K | -2035% |
| Total assets | SEK 136K | -26% |
| Equity | SEK 28K | -44% |
| Employees | 0 | — |
Legal name
IK BioCeuticals AB
Org number
5569366007
Legal form
Aktiebolag
NACE code
6421 · Activities of holding companies
Founded
2 juli 2013
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolagets skall bedriva försäljning av näringsprodukter samt hälsokontroller genom provtagning och utbildning inom näring och hälsa i Sverige, Norden och övriga Europa och därmed förenlig verksamhet.
Address
Köpmangatan 38
Email
anette@adbokforingsbyra.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 13 | 64 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −2 | — | — | −2 | −23 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | −2 | 0 | 0 | −2 | −23 |
| Net financials | — | — | 0 | 1 | 1 |
| Profit before tax | −2 | 0 | 0 | −1 | −22 |
| Tax | −0 | −0 | — | — | — |
| Net profit | −2 | 0 | 0 | −1 | −22 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 61 | 61 | 60 | 185 | 136 |
| Equity | 36 | 36 | 52 | 51 | 28 |
| Long-term debt | 0 | 0 | — | — | 0 |
| Short-term debt | 25 | 26 | 8 | 134 | 107 |
| Total debt | 25 | 26 | 8 | 134 | 108 |
EBITDA margin
-35.5%
This company
15.8%
Market median
-325% vs market
20202024
Equity ratio
20.9%
This company
38.2%
Market median
-45% vs market
20202024
Return on equity
-78.2%
This company
18.4%
Market median
-525% vs market
20202024
Net profit margin
-34.6%
This company
8.1%
Market median
-527% vs market
20202024
Asset turnover
0.47×
This company
1.12×
Market median
-58% vs market
20202024
Debt / equity
3.78×
This company
0.62×
Market median
-510% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-09-01 – 2020-08-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Deputy Board Member | 2022 | |
| Chairman | 2022 | |
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
| Former (2) | ||
| Deputy Board Member | 2022 – 2022 | |
| Board of Directors | 2022 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of IK BioCeuticals AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Erik Gunnar Rasmus Tibell | Deputy Board Member | 0 companies |
| Anette Christin Berglind | Chairman | 0 companies |
| Cecilia Marie-Louise Margaretha Tibell | Board of Directors | 0 companies |
| Carlo Henich Hiltunen | Deputy Board Member | 0 companies |
| Jari-Pekka Dujsel | Deputy Board Member | 0 companies |
| Lena Åkerstedt | Board of Directors | 0 companies |